IBD significantly impacts millions of people, severely reducing their quality of life due to the incapacitating nature of symptoms. Recent advancements in IBD treatment emphasize targeted therapies that more accurately address the underlying mechanisms of the disease. The shift towards personalized medicine represents a novel approach, using genetic, microbiome, and pharmacogenomic information to tailor treatments, enhance effectiveness, minimize side effects, and improve overall healthcare outcomes.